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Abstract
Clostridium difﬁcile infection (CDI) is a potentially fatal illness with an increasing incidence worldwide. Despite extensive ongoing research
into CDI treatment, management of CDI still poses important problems, such as a high propensity to relapse and refractoriness to
treatment, especially when there is an ileus and oral drugs cannot be adminstered. This guideline evaluates the available literature, dis-
cusses criteria for disease severity and provides recommendations for CDI treatment, indicating level of evidence and strength of rec-
ommendation.
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Summary of deﬁnitions and
recommendations
Deﬁnitions
Episode of CDI :
1. a clinical picture compatible with CDI and microbiologi-
cal evidence of toxin-producing Clostridium difﬁcile in
stool without evidence of another cause of diarrhoea or
2. pseudomembranous colitis (as diagnosed during endos-
copy, after colectomy or on autopsy)
Clinical pictures compatible with CDI:
1. diarrhoea :
a. loose stools, i.e. taking the shape of the receptacle or
corresponding to Bristol stool chart types 5–7 and
b. a stool frequency perceived as too high by the patient
2. ileus :
a. signs of severely disturbed bowel passage such as vomit-
ing and absence of stool and
b. radiological signs of bowel distension
3. toxic megacolon :
a. radiological signs of distension of the colon and
b. signs of a severe systemic inﬂammatory response
Signs of severe colitis:
• fever (core body temperature > 38.5C)
• rigors (uncontrollable shaking and a feeling of cold fol-
lowed by a rise in body temperature)
• hemodynamic instability including signs of septic shock
• signs of peritonitis, including decreased bowel sounds,
abdominal tenderness, rebound tenderness and guarding
• signs of ileus, including vomiting and absent passage of
stool
• marked leukocytosis (leukocyte count > 15 · 109/L)
• marked left shift (band neutrophils > 20% of leukocytes)
• rise in serum creatinine (>50% above the baseline)
• elevated serum lactate
• pseudomembranous colitis (endoscopy)
• distension of large intestine (imaging)
• colonic wall thickening including low-attenuation mural
thickening (imaging)
• pericolonic fat stranding (imaging)
• ascites not explained by other causes (imaging)
Severe CDI :
an episode of CDI with one or more signs of severe
colitis.
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CDI without signs of severe colitis in patients with
advanced age (‡65), serious comorbidity, ICU admission, or
immunodeﬁciency may be regarded as severe.
CDI treatment response :
1. stool frequency as perceived by the patient decreases or
stool consistency improves after 3 days and
2. no new signs of severe colitis develop
CDI treatment failure :
absence of CDI treatment response
CDI recurrence :
1. stool frequency as perceived by the patient increases for
two consecutive days and stools become looser or new
signs of severe colitis develop and
2. microbiological evidence of toxin-producing C. difﬁcile in
stools without evidence of another cause of diarrhoea
after an initial CDI treatment response
Recommendations
(implementation category between brackets)
1. Antiperistaltic agents and opiates should be avoided. (B-II)
2. In general, strive to use antibiotics covering a spectrum
no broader than necessary and narrow the antibiotic
spectrum of treatment after results of cultures and/or
susceptibility tests become known. (B-III)
3. Mild CDI (stool frequency < 4 times daily; no signs of
severe colitis), clearly induced by the use of antibiotics,
may be treated by stopping the inducing antibiotic.
Observe patients closely for any signs of clinical deteriora-
tion and place on therapy immediately if this occurs. (B-III)
4. Treatment for an initial episode and a ﬁrst recurrence of
CDI:
If oral therapy is possible:
• non-severe: metronidazole 500 mg tid orally for
10 days (A-I)
• severe: vancomycin 125 mg qid orally for 10 days (A-I)
If oral therapy is impossible:
• non-severe: metronidazole 500 mg tid intravenously
for 10 days (A-III)
• severe: metronidazole 500 mg tid intravenously for
10 days (A-III) + intracolonic vancomycin 500 mg in
100 mL of normal saline every 4–12 h (C-III) and/or
vancomycin 500 mg qid by nasogastric tube (C-III)
5. Colectomy should be performed to treat CDI in any of
the following situations:
• perforation of the colon
• systemic inﬂammation and deteriorating clinical condi-
tion not responding to antibiotic therapy; this includes
the clinical diagnoses of toxic megacolon and severe
ileus. Colectomy should preferably be performed
before colitis is very severe. Serum lactate may, inter
alia, serve as a marker for severity (operate before lac-
tate exceeds 5.0 mmol/L).
6. Treatment for a second recurrence of CDI and later
recurrences:
If oral therapy is possible:
• vancomycin 125 mg qid orally for at least 10 days (B-II)
• consider a taper (for example, decreasing daily dose
with 125 mg every 3 days)/pulse (for example, a dose
of 125 mg every 3 days for 3 weeks) strategy (B-II)
If oral therapy is impossible:
• metronidazole 500 mg tid intravenously for 10–14 days
(A-III) plus retention enema of vancomycin 500 mg in
100 mL of normal saline every 4–12 h (C-III) and/or
vancomycin 500 mg qid by nasogastric tube (C-III)
7. In all the above-mentioned cases, oral vancomycin may be
replaced by teicoplanin 100 mg twice daily, if available.
Introduction
Clostridium difﬁcile infection (CDI) may arise when a patient’s
bowel is colonized by C. difﬁcile after ingestion of spores; the
spores subsequently germinate and the vegetative bacteria
start producing toxins. Colonization is inhibited by the nor-
mal intestinal ﬂora, which is hypothesized to compete with
C. difﬁcile for nutrients and space on the mucosal surface.
Therefore, the use of antibiotics is the most important risk
factor for CDI. The vegetative state of the bacterium is
resistant to a varying but broad range of antibiotics and the
spores are highly resistant to antibiotics and can withstand
many forms of chemical attack, e.g. most high-level disinfec-
tants. The most important problem in treating CDI is the
high recurrence rate. Various factors, such as the need to
continue treatment with the inciting antibiotic, have been
associated with this (see ‘Prognostic criteria and criteria for
disease severity’). The antibiotics needed to kill the vegeta-
tive bacteria do not kill the spores and might even contrib-
ute to recurrence by disrupting the normal gut ﬂora even
further. Individuals who suffer a recurrence may enter a
repetitive cycle of recurrences, leading to exhaustion and
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protein-losing enteropathy. A second problem in treating
CDI is the fact that, in severe forms of CDI, antibiotics may
fail, resulting in progressive colitis with high morbidity and
mortality. Several factors may play a role in this, such as a
time lag for antibiotics to reach adequate intracolonic levels
[1] and possibly the fact that a systemic inﬂammatory
response due to severely damaged colonic mucosa may per-
sist some time after removal of the etiological agent.
Objective
Since treatment of CDI can be complicated by these many
problems, the need for this evidence-based guideline seems
obvious. The objective of this study was to evaluate the
available evidence concerning treatment of CDI and formu-
late recommendations for treatment.
Update Methodology
Studies on CDI treatment were found with a computerized
literature search of PUBMED using the terms ‘Clostridium dif-
ﬁcile AND (treatment OR trial)’. All randomized and non-
randomized trials investigating the effect of an intervention
on the clinical outcome (resolution or recurrence of diar-
rhoea; incidence of complications) of CDI published in any
language were included. Studies investigating carriage or
other purely microbiological parameters were not consid-
ered sufﬁcient evidence for treatment strategies. The result-
ing literature from 1978 was reviewed and analyzed.
Furthermore, systematic reviews from the Cochrane Library
and the guidelines of the Infectious Diseases Society of
America (IDSA) were evaluated. Recommendations were
based on a systematic assessment of the quality of evidence.
For indicating the quality of evidence and weight of recom-
mendations the system of the Canadian Task Force on the
Preventative Health Care was used (Table 1).
Deﬁnitions
Criteria for the diagnosis of CDI
Pseudomembranous colitis, which is an endoscopic diagnosis,
is caused by C. difﬁcile in the vast majority of cases and
therefore may sufﬁce for the diagnosis of CDI in the absence
of an obvious other cause. In the rest of the cases, a combi-
nation of symptoms and signs, in conjunction with microbio-
logical evidence of toxin-producing C. difﬁcile in stools and
the absence of another cause is necessary. Compatible clini-
cal pictures are diarrhoea, ileus and toxic megacolon. Diar-
rhoea is deﬁned as loose stools, i.e. taking the shape of the
receptacle or corresponding to Bristol stool chart types 5–7
[2], plus a stool frequency perceived as too high by the
patient. Faecal incontinence may be a part of the disease.
Ileus in the context of CDI is deﬁned as signs of severely dis-
turbed bowel passage such as vomiting and absence of stool,
combined with radiological signs of bowel distension. Toxic
megacolon is deﬁned as radiological signs of distension of the
colon combined with signs of a severe systemic inﬂammatory
response. The above-mentioned criteria are largely in line
with the recommendations of the American Ad Hoc C. difﬁ-
cile surveillance working group [3] and the European Study
Group for C. difﬁcile [4].
Prognostic criteria and criteria for disease severity
Outcome measures of CDI comprise complications, mortal-
ity and recurrences. It is difﬁcult to set a rigid set of criteria
for the assessment of prognosis and severity of CDI. First,
surprisingly little research has been done on clinical predic-
tors of outcome. Second, prognostic markers have not been
validated in prognostic studies. Third, prognosis depends on
disease severity and other prognostic factors, such as age,
comorbidity, admission to an intensive care unit, and anti-
peristaltic and immunosuppressive medication. It is unknown
what the weight of these prognostic factors is in comparison
with assessed disease severity.
Possible features of severe colitis that have been linked to
a higher chance of recurrence are faecal incontinence [5],
the endoscopic ﬁnding of pseudomembranous colitis [6], and
longer cumulative duration of previous episodes of CDI [7].
Leukocytosis (leukocyte count > 20 · 109/L) has been asso-
ciated with a high mortality rate in CDI [8], a complicated
course [9], refractoriness to therapy [6] and risk of recur-
rence [9]. Hypoalbuminaemia (<25 g/L) has also been associ-
ated with a high mortality rate in CDI [8] and refractoriness
to therapy [6,10,11]. However, since it may be seen as a
result of malnutrition or protein-losing enteropathy in
TABLE 1. Strength of recommendation and quality of
evidence according to the Canadian Task Force on Pre-
ventative Health Care
Strength of recommendation
A: Good evidence to support a recommendation
B: Moderate evidence to support a recommendation
C: Poor evidence to support a recommendation
Quality of evidence
I: Evidence from ‡one properly randomized, controlled trial
II: Evidence from ‡one well-designed clinical trial, without randomization; from
cohort or case-controlled analytic studies (preferably from ‡one centre); from
multiple time-series; or from dramatic results from uncontrolled experiments
III: Evidence from opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert committees
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longstanding disease, as a negative acute phase protein in
acute disease, and as a marker for comorbidity (e.g. liver
cirrhosis, nephrotic syndrome, wasting) this feature may be
too heterogeneous to be a reliable marker of severe disease.
Factors associated with unfavourable outcome that are not
direct markers of severe colitis include advanced age, comor-
bidity, a decreased antibody response, gastric acid suppres-
sants, and the need to prolong inciting antibiotic therapy.
Advanced age has been associated with a complicated course
[12] and recurrence [9,12]. Comorbidity has been associated
with a high mortality rate [8] and a higher chance of recur-
rence [13]. A decreased humoral immune response against
Clostridial toxins TcdA and TcdB has been associated with a
higher chance of recurrence and longer duration of symptoms
[14,15], although other studies did not ﬁnd this association.
Use of H2-antagonists has been associated with a higher
chance of recurrence [5] and use of proton pump inhibitors
has been associated with refractoriness to therapy [16]. Also,
the need to continue the use of inciting antibiotic has been
associated with refractoriness to therapy [16]. However, it is
unclear whether the use of gastric acid suppressants and the
need to continue antibiotics have a causal relationship with
unfavourable outcome or whether they are markers of more
severe comorbidity. Obviously, admission to an ICU is an
unfavourable prognostic factor [6,11].
Markers of severe colitis
Markers that could reasonably be assumed to correlate posi-
tively with the severity of colitis are mentioned below,
although we must stress that the prognostic value of these
markers is uncertain. Obviously, markers should not be
attributable to a concomitant disease, if they are to be
regarded as a marker of severe CDI. Ideally, markers should
be obtainable at the earliest stage in the disease course to
be a predictor of outcome.
Physical examination.
• fever (core body temperature > 38.5C)
• rigors (uncontrollable shaking and a feeling of cold fol-
lowed by a rise in body temperature)
• haemodynamic instability including signs of distributive
(vasodilatory, septic) shock
• signs of peritonitis, including decreased bowel sounds,
abdominal tenderness, rebound tenderness and guarding
• signs of ileus including vomiting and absent passage of
stool
Admixture of blood with stools is rare in CDI and the
correlation with severity of disease is uncertain.
Laboratory investigations.
• marked leukocytosis (leukocyte count > 15 · 109/L)
• marked left shift (band neutrophils > 20% of leukocytes)
• rise in serum creatinine (>50% above the baseline)
• elevated serum lactate
Colonoscopy or sigmoidoscopy.
• pseudomembranous colitis
There is insufﬁcient knowledge concerning the correlation of
endoscopic ﬁndings compatible with CDI, such as oedema,
erythema, friability and ulceration, and the severity of dis-
ease.
Imaging.
• distension of large intestine
• colonic wall thickening including low-attenuation mural
thickening
• pericolonic fat stranding
• ascites not explained by other causes
The correlation of haustral or mucosal thickening, including
thumbprinting, pseudopolyps and plaques, with severity of
disease is unclear.
Prognostic markers other than disease severity
• advanced age (‡65)
• serious comorbidity and ICU admission
• immunodeﬁciency
Criteria for response, failure and recurrence in the treat-
ment of CDI
Treatment response is present when either stool frequency
decreases or stool consistency improves, and parameters of
disease severity (clinical, laboratory, radiological) improve,
and no new signs of severe disease develop. In all other cases,
treatment is considered a failure. It is only reasonable to eval-
uate treatment response after at least 3 days, assuming that
the patient is not worsening on treatment. Treatment with
metronidazole, in particular, may result in a clinical response
only after 3–5 days [1,16]. After clinical response, it may take
weeks for stool consistency and frequency to become
entirely normal [17]. Recurrence is present when, after an
initial response, stool frequency increases for two consecu-
tive days and stools become looser, or new signs of severe
disease develop and microbiological evidence of toxin-pro-
ducing C. difﬁcile in stool is present without evidence of
another cause. It is impossible to distinguish recurrence due
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to relapse (renewed symptoms from already present CDI)
from recurrence due to reinfection in daily practice.
Overview of Medical Treatment Options
Available for CDI
There is an increasing body of evidence concerning treatment
of CDI, both initial (Table 2 [6,18–32], Table 3 [17,33–36] and
Table 4 [9,11,13,15,37–48]) and recurrent episodes (Table 5
[33,49–52] and Table 6 [7,53–68]). Tables 2, 3 and 5 report
the evidence from randomized trials, with comments on meth-
odology. It is difﬁcult to compare these studies because of
differences in diagnostic criteria, exclusion of co-pathogens,
severity of CDI, co-morbidity, inciting antibiotics and con-
comitant use of antibiotics. Moreover, these studies usually
have endpoints of clinical cure or microbiological cure. How-
ever, the deﬁnition of clinical cure and recurrence is highly
variable. Patients seldom have normal stools directly after
treatment of CDI. With respect to microbiological cure, the
signiﬁcance of persistently or recurrently positive stool toxin
tests or cultures is not clear. Furthermore, it is not possible
to distinguish relapse from reinfection. Lastly, the number of
participants in most trials is small. In conclusion, we need
more randomized controlled trials on CDI treatment.
It is important to realize that several experimental treat-
ment options are not widely available, such as toxin-binding
resins and polymers and speciﬁc immunotherapy.
Discontinuing the inciting antibiotic without antibiotic
treatment
The rate of spontaneous resolution is unknown in patients
with mild CDI. In one study [40], the spontaneous recovery
rate in hospitalized patients with diarrhoea and a positive
toxin assay who did not undergo endoscopy or had no
pseudomembranous colitis on colonoscopy was 33%. More
antibiotics after discontinuing the inciting antibiotic might
increase the chance of subsequent recurrence, since gut ﬂora
will be exposed to a second antibiotic with a different spec-
trum (i.e. metronidazole). It may therefore be prudent to
discontinue the inciting antibiotic only in the case of mild
CDI, while closely monitoring the patient.
Oral antibiotics
There is only one placebo-controlled trial investigating the
effectiveness of antibiotics for CDI and it had very few partici-
pants. Several antibiotics have been compared to each other.
Oral administration of the glycopeptides vancomycin and
teicoplanin appears most effective in inducing both clinical
cure and microbiological cure, especially in severe CDI. The
difﬁculty is how to deﬁne severe CDI. In one prospective, ran-
domized, and blinded study [6], which evaluated the efﬁcacy of
vancomycin vs. metronidazole according to disease severity,
the diagnosis of severe CDI was based on age, body tempera-
ture, albumin level and leukocyte count. Vancomycin proved
to be superior to metronidazole in cases of severe CDI. Two
trials investigating the efﬁcacy of the toxin-binding polymer,
tolevamer [34,35], also showed the superiority of oral vanco-
mycin over metronidazole in severe cases. A recent Cochrane
systematic review [70] has examined the available literature
on antibiotic treatment options for CDI and concluded that
teicoplanin is the most effective antibiotic treatment for
moderate to severe CDI and vancomycin has no superiority
over metronidazole. However, this review did not include the
above-mentioned recent studies. It seems likely that the effec-
tiveness of teicoplanin and vancomycin is in the same range.
Oral metronidazole is also very effective in inducing a
response and has the advantage of low cost and the fact that
it may contribute less to the emergence of vancomycin-resis-
tant enterococci.
If metronidazole is indeed less effective than glycopeptides,
this may be explained by the low levels metronidazole
reaches in the colon, since it is absorbed in the small intes-
tine and then excreted again in the bile and in the inﬂamed
colon, whereas glycopeptides are not absorbed. Different
doses of oral vancomycin have been used, but only one small
randomized trial [22] has compared high- vs. low-dose
vancomycin and found no statistically signiﬁcant difference.
Since low doses of oral vancomycin result in high concentra-
tions in stool, there is no need to treat with high doses,
except in an attempt to reach sufﬁcient concentrations in
the colon when administering vancomycin by nasogastric
tube in a patient with ileus. Given the poor faecal concentra-
tions of metronidazole achieved following a 500 mg 8-hourly
dose, lower doses (e.g. 250 mg at a 6–8 hourly dose) should
be less effective. Several studies, however, have used lower
doses, usually with good results [6,7,19,27,28,34,35]. Even a
modest increase in the MIC of metronidazole for C. difﬁcile
might result in insufﬁcient faecal antibiotic concentrations to
inhibit (vegetative) bacteria. Metronidazole resistance is to
be regarded as exceedingly rare. However, the emergence of
reduced susceptibility to metronidazole has recently been
reported in UK C. difﬁcile strains [1,71,72]. No reduced sus-
ceptibility to vancomycin was observed. The exact mecha-
nism of reduced susceptibility to metronidazole remains to
be determined. Notably, there is also evidence that inactiva-
tion of metronidazole occurs in the presence of gut con-
tents, possibly due to metabolism by enterococci [73].
Oral bacitracin and fusidic acid seem to be less effective
than vancomycin and metronidazole, respectively, although
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this has not convincingly been demonstrated. Currently,
there is insufﬁcient evidence to advocate the use of the rifa-
mycin derivative rifaximin, to which resistance has been
noted, and the antiprotozoal/anthelminthic nitazoxanide,
which has been shown to be statistically similar to metroni-
dazole in a small prospective randomized trial [28], but
TABLE 2. Randomized controlled trials of antibiotic treatment of initial CDI. Initial cure rate as a percentage of all patients
and relapse rate as a percentage of initially cured patients
Trial Treatment Number of patients Cure (%) Relapse (%)
Keighley et al. [18] Vancomycin 125 mg qid, 5 days 9 78 0
Placebo 7 14 –
No clear case deﬁnition. No description of allocation of treatment. Only data of patients with toxin-positive stool shown. Unclear length of
follow-up and incidence or relapse in placebo group. p <0.02 for comparison of cure rates
Teasley et al. [19] Vancomycin 500 mg qid, 10 days 32 100 19
Metronidazole 250 mg qid, 10 days 32 97 6
Only data of patients with toxin-positive stools or pseudomembranous colitis shown. Per-protocol analysis. Follow-up 21 days. Differences
not statistically signiﬁcant
Young et al. [20] Vancomycin 125 mg qid, 7 days 21 86 33
Bacitracin 20 000 U qid, 7 days 21 76 42
Double-blind. 25% drop-out during follow-up of bacitracin group. Follow-up 5 weeks. Differences not statistically signiﬁcant
Dudley et al. [21] Vancomycin 500 mg qid, 10 days 15 100 20
Bacitracin 25 000 U qid, 10 days 15 80 42
Double-blind. Patients had leukocytosis, fever or abdominal pain. 29% drop-out in vancomycin group, 12% in bacitracin
group. Per-protocol analysis. Unclear deﬁnition of failure (‘worsening during treatment’). Failing patients crossed over to alternate drug.
Interruption of study drug in vancomycin group for a mean of 2.8 days and in bacitracin group for a mean of 1.8 days. Unclear length of
follow-up. Differences not statistically signiﬁcant
Fekety et al. [22] Vancomycin 125 mg qid, mean 10.6 days 24 100 21
Vancomycin 500 mg qid, mean 10.1 days 22 100 18
Variable duration of therapy. 18% dropout rate. Per-protocol analysis. Unclear length of follow-up. Differences not statistically
signiﬁcant
Boero et al. [23] Vancomycin 500 mg bid, 10 days 10 100 –
Rifaximin 200 mg tid, 10 days 10 90 –
Article in Italian. Patients had diarrhoea, abdominal pain and fever. No description of allocation of treatment. Unclear deﬁnition of cure.
Differences not statistically signiﬁcant
de Lalla et al. [24] Vancomycin 500 mg qid, 10 days 20 100 20
Teicoplanin 100 mg bid, 10 days 26 96 8
No description of allocation of treatment. Per-protocol analysis. Unclear length of follow-up. Differences not statistically signiﬁcant
Wistro¨m [25] Teicoplanin 100 mg qid, 3 days, followed by 100 mg bid, 4 days 24 96 35
Teicoplanin 100 mg bid, 7 days 23 70 50
Double-blind. Outcome of ‘improvement, but not cure’ (2 loose stools per day or 1 loose stool per day with fever or cramps) was counted
as failure. Three patients with improvement in bid group; 1 in qid group. Follow-up 5 weeks. p 0.02 for comparison of cure rates. Relapse
rates not statistically different
Wenisch et al. [26] Vancomycin 500 mg tid, 10 days 31 94 17
Metronidazole 500 mg tid, 10 days 31 94 17
Teicoplanin 400 mg bid, 10 days 28 96 7
Fusidic acid 500 mg tid, 10 days 29 93 30
Follow-up 30 days. Only statistically signiﬁcant difference was relapse rate of fusidic acid vs. teicoplanin (p 0.042)
Wullt [27] Metronidazole 400 mg tid, 7 days 55 93 30
Fusidic acid 250 mg tid, 7 days 59 83 30
Double-blind. 13% drop-out during treatment; 15% further drop-out during follow-up. Per-protocol analysis. Follow-up 35 days.
Differences not statistically signiﬁcant
Musher et al. [28] Metronidazole 250 mg qid, 10 days 34 82 30
Nitazoxanide 500 mg bid, 7 days 40 90 26
Nitazoxanide 500 mg bid, 10 days 36 89 16
No deﬁnition of relapse. Double-blind. 23% drop-out during treatment. Per-protocol analysis. Follow-up 31 days. Differences not statistically
signiﬁcant
Lagrotteria et al. [29] Metronidazole 500 mg tid, 10 days 20 65 38
Metronidazole 500 mg tid + rifampicin 300 mg bid, 10 days 19 63 42
Intention-to-treat analysis. Follow-up 40 days. Differences not statistically signiﬁcant
Zar et al. [6] Vancomycin 125 mg qid, 10 days 71 97 7
Metronidazole 250 mg qid, 10 days 79 84 14
Double-blind. 13% drop-out during treatment. Per-protocol analysis. Follow-up 21 days. p 0.006 for comparison of cure rates. p
0.27 for comparison of relapse rates. The original protocol was stratiﬁed in a group with mild and a group with severe disease (based on
age, fever, albumin level and leukocyte count), which resulted in a larger difference between cure rates in the group with severe disease and
a statistically non-signiﬁcant difference between cure rates in the group with mild disease
Louie et al. [30] Fidaxomicin 50 mg bid, 10 days 14 71 8
Fidaxomicin 100 mg bid, 10 days 15 80 0
Fidaxomicin 200 mg bid, 10 days 16 94 6
Open-label. Patients with signs of highly severe CDI (>12 bowel movements per day, vomiting, severe abdominal tenderness, ileus,
WBC > 30, toxic megacolon) were excluded. Cure = complete resolution of diarrhoea. Follow-up 6 weeks after end of treatment
Musher et al. [31] Vancomycin 125 mg qid, 10 days 27 74 7
Nitazoxanide 500 mg bid, 10 days 22 77 5
CDI = stool EIA for toxin A or B positive AND (temperature > 38.3C OR abdominal pain OR leukocytosis). Patients with >1 episode in
preceding 6 months. 12% dropout rate during treatment. Double-blind, placebo-controlled. Modiﬁed intention-to-treat analysis.
Industry-sponsored. Cure = complete resolution of symptoms during 3 days after completion of therapy. Per-protocol analysis: 87% vs. 94%
cure. Follow-up 31 days after start of treatment. No differences in severity subgroups. Differences not statistically signiﬁcant
Louie et al. [32] Vancomycin 125 mg qid, 10 days 284 90 24
Fidaxomicin 200 mg bid, 10 days 265 92 13
Unpublished trial
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whose non-inferiority to vancomycin could not be shown in
another trial due to lack of power [31]. As yet, there is also
insufﬁcient evidence to justify routine use of ﬁdaxomicin
(OPT-80), an inhibitor of RNA polymerase of gram-positive
bacteria, although preliminary results of a recently presented
study are very promising [32].
TABLE 3. Randomized controlled trials of non-antibiotic treatment of initial CDI. Initial cure rate as a percentage of all
patients and relapse rate as a percentage of initially cured patients
Trial Treatment
Number
of patients
Cure
(%)
Relapse
(%)
Probiotics
McFarland et al. [33] Vancomycin or metronidazole + Saccharomyces
boulardii 2 · 1010 CFU/day, 4 weeks
31 – 19
Vancomycin or metronidazole + placebo 33 – 24
Double-blind. No control for type, duration or dose of antibiotic. Unclear deﬁnition of relapse. Follow-up 8 weeks after start of
treatment. p 0.86 for comparison of relapse rates
Toxin-binding resins and polymers
Louie et al. [17] Tolevamer 1 g tid, 14 days + placebo 94 60 16
Tolevamer 2 g tid, 14 days + placebo 91 79 7
Vancomycin 125 mg qid, 10 days + placebo 94 91 19
Non-inferiority trial. Patients with stool frequency >12 per day or abdominal pain were excluded. Tolevamer could be prolonged
when inciting antibiotic could not be stopped. Double-blind. 23% drop-out. Per-protocol analysis. Cure rate of
tolevamer 2 g non-inferior in comparison with vancomycin (Chow-test p 0.03). Non-inferiority of tolevamer 1 g compared with
vancomycin could not be demonstrated. p 0.05 for comparison of relapse rates of tolevamer 2 g with vancomycin. Relapse rates of
tolevamer 1 g and vancomycin not statistically different. Follow-up 6–8 weeks
Louie et al. [34] Tolevamer 3 g tid, 14 days 266 47 3
Vancomycin 125 mg qid, 10 days 134 81 23
Metronidazole 375 mg qid, 10 days 143 72 27
Unpublished trial
Bouza et al. [35] Tolevamer 3 g tid, 14 days 268 42 6
Vancomycin 125 mg qid, 10 days 125 81 18
Metronidazole 375 mg qid, 10 days 135 73 19
Unpublished trial
Immunotherapy
Lowy [36] MDX-066 and MDX-1388
(intravenously administered monoclonal antibodies
against TcdA and TcdB) after standard antimicrobial
therapy
101 – 7
Placebo after standard antimicrobial therapy 99 – 25
Unpublished trial. Follow-up 12 weeks
TABLE 4. Observational studies of treatment of initial CDI.
Trial Treatment
Number
of patients
Cure
(%)
Relapse
(%)
Antibiotics
Bartlett et al. [37] Vancomycin 79 96 14
Silva et al. [38] Vancomycin 16 100 13
Cherry et al. [39] Metronidazole 13 100 15
Bartlett [40] Vancomycin 189 97 24
de Lalla et al. [41] Vancomycin 500 mg qid, 10 days 23 100 13
Teicoplanin 200 mg bid, 10 days 22 100 0
Olson et al. [42] Metronidazole 632 98 6
Vancomycin 122 99 10
Kyne et al. [15] Metronidazole 44 ? 50
Fernandez et al. [11] Metronidazole 99 62 ?
Musher et al. [43] Metronidazole 207 78 28
Pe´pin et al. [9] Metronidazole 1123 84 29
Vancomycin 112 ? 28
Louie [44] Diﬁmicin varying dose 45 91 5
Musher et al. [45] Nitazoxanide 500 mg bid, 10 days 35 74 27
Patients ﬁrst failed metronidazole
Al Nassir et al. [16] Metronidazole 34 >90 12
Ten patients switched to vancomycin
Vancomcyin 18 >90 11
Herpers et al. [46] Tigecycline varying duration 4 100 0
Severe CDI. Follow-up at least 3 months
Toxin-binding resins and polymers
Mogg et al. [47] Colestipol 10 g qid, 5 days 12 25 –
Originally set up as a randomized placebo-controlled trial. Placebo group was merged with historical control, however. Only six patients had
toxin-positive stool
Passive immunotherapy with immune whey
van Dissel et al. [48] Metronidazole or vancomycin followed by immune whey protein concentrate, 14 days 16 100 0
56% of patients had recurrent CDI; mean follow-up 333 days
Numan et al. [13] Metronidazole or vancomycin followed by immune whey protein concentrate, 14 days 109 100 10
109 episodes; 101 patients; 40% of patients had recurrent CDI
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Duration of antibiotic therapy
The duration of antibiotics has been 10 days in most studies.
Occasionally, a shorter duration (e.g. 7 days) has been
reported. We feel that there is insufﬁcient evidence of suc-
cess with a shorter duration of therapy with any antibiotic
to consider shorter regimens a treatment option.
There is no deﬁnitive evidence that taper or pulse regi-
mens with vancomycin are effective in reducing the incidence
of relapses. This strategy is mainly based on favourable expe-
rience and the theoretical rationale that spores can still ger-
minate long after the clinical symptoms have resolved.
McFarland et al. [7] retrospectively compared a standard
course of antibiotics, vancomycin taper strategies (gradually
decreasing the daily dose of vancomycin by 125–750 mg per
day from varying starting doses) and vancomycin pulse strat-
egies (125–500 mg of vancomycin every 2–3 days during a
period of usually 3 weeks). They found the recurrence rate
to be lowest in pulse regimens (14%), followed by taper regi-
mens (31%) and the standard regimen of vancomycin (54%;
average for all dose groups). No other studies investigating
taper or pulse regimens have been published. Further studies
are needed.
Probiotics
Probiotics may be of value when added to antibiotics, but
the studies that have investigated this have major draw-
backs such as small numbers, non-randomized allocation of
antibiotics to which the probiotics were added, and lack
of homogeneity among study groups. This is also the con-
clusion reached by a recent Cochrane systematic review
[74]. Therefore, there is insufﬁcient evidence to recom-
mend the addition of probiotics to antibiotics. In addition,
several studies of invasive disease have been reported,
resulting from the use of probiotics such as Saccharomyces
boulardii in debilitated or immunocompromised patients
[75,76]. Moreover, probiotics were associated with
increased mortality, partly due to nonocclusive mesenterial
ischemia, in a randomized controlled trial in acute pancrea-
titis [77].
Treatment when oral administration is not possible
The only parenteral antibiotic therapy for CDI, supported by
case series, is metronidazole [78]. Several case reports
regarding the use of intravenous immunoglobulin have been
published, but the data do not provide sufﬁcient evidence to
support its use. Thus, it is unknown how to best treat
patients with ileus due to CDI. There are some anecdotal
reports on delivery of vancomycin to the gut by means other
than orally, mainly through intracolonic delivery. Questions
regarding the efﬁcacy, optimal dosing and duration of treat-
ment with intracolonic vancomycin are unanswered. The
introduction of faecal collector drainage systems has facili-
tated the use of glycopeptide retention enemas in ICUs, but
they are very expensive. Tigecycline appeared useful as sal-
vage therapy, as reported in a recent case series of patients
with severe CDI complicated by ileus, but these promising
ﬁndings require conﬁrmation in prospective clinical trials
[46]. Faecal transplantation has been performed through
TABLE 5. Randomized controlled studies of treatment of recurrent CDI
Trial Treatment
Number
of patients
Failurea
(%)
Probiotics
McFarland et al. [33] Vancomycin or metronidazole + Saccharomyces boulardii 2 · 1010 CFU/day, 4 weeks 26 35
Vancomycin or metronidazole + placebo 34 65
Double-blind. No control for type, duration or dose of antibiotic. Unclear deﬁnition of relapse. Follow-up 8 weeks after start of treatment.
p 0.04 for comparison of failure rates
Surawicz et al. [49] Vancomycin 500 mg qid, 10 days, followed by Saccharomyces boulardii 2 · 1010 CFU/day, 4 weeks 18 17
Vancomycin 500 mg qid, 10 days, followed by placebo 14 50
Vancomycin 125 mg qid, 10 days, followed by Saccharomyces boulardii 2 · 1010 CFU/day, 4 weeks 45 51
Vancomycin 125 mg qid, 10 days, followed by placebo 38 45
Metronidazole 1 g/day, 10 days, followed by Saccharomyces boulardii 2 · 1010 CFU/day, 4 weeks 27 48
Metronidazole 1 g/day, 10 days, followed by placebo 26 50
Follow-up 5 months after completion of study drug. p 0.05 for the comparison of failure rates in patients who received 500 mg of
vancomycin qid. Drop-out was 22%. No further statistically signiﬁcant differences
Wullt et al. [50] Metronidazole 400 mg tid, 10 days + Lactobacillus plantarum 299v 5 · 1010 CFU/day, 38 days 12 42
Metronidazole 400 mg tid, 10 days + placebo 9 67
Double-blind. 28% cent drop-out. Follow-up 70 days. Difference not statistically signiﬁcant
Lawrence et al. [51] Vancomycin or metronidazole followed by Lactobacillus GG 6 · 1011 CFU/day, 21 days 8 38
Vancomycin or metronidazole followed by placebo 7 14
Patients blinded. No control for type, duration or dose of antibiotic. Follow-up 60 days after completion of antibiotic. Difference not
statistically signiﬁcant
Passive immunotherapy with immune whey
Mattila et al. [52] Colostral immune whey 200 mL tid + placebo, 14 days 18 44
Metronidazole 400 mg tid + placebo, 14 days 20 45
Double-blind. Multi-centre trial. Follow-up 70 days. Difference not statistically signiﬁcant.
aNon-response or relapse.
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instillation with a colonoscope or enemas, but there is insuf-
ﬁcient evidence to recommend this.
There are no prospective studies assessing which CDI
patients beneﬁt from surgical intervention. One study found
that colectomy was most successful at a relatively early stage
of the disease, i.e. before lactate exceeds 5.0 mmol/L [79].
Recommendations for the Treatment of
CDI
Recommendations for medical treatment of initial CDI
In the case of mild CDI (stool frequency < 4 times daily; no
signs of severe colitis), clearly induced by the use of antibiot-
ics, it is acceptable to discontinue the inducing antibiotic and
observe the clinical response, but patients must be followed
very closely for any signs of clinical deterioration and placed
on therapy immediately if this occurs. Theoretic rationale,
anecdotic evidence, and one case-control study suggest that
antiperistaltic and opiate agents should be avoided, especially
in the acute setting [80]. There is no evidence that switching
to ‘low-risk’ antibiotics when the antibiotic treatment that
cited the episode of CDI cannot be discontinued, nor its
spectrum narrowed, is effective. It seems rational, however,
to always strive to use antibiotics covering a spectrum no
broader than necessary. When the inciting antibiotic cannot
be discontinued, antibiotic treatment for CDI should be initi-
ated. Furthermore, there is no proof that discontinuing
gastric acid suppressants is effective, either.
In all cases other than mild CDI medical treatment for CDI
should be started. Antibiotics may be started while awaiting
diagnostics when there is sufﬁcient clinical suspicion. We
recommend treatment of an initial episode of CDI with the fol-
lowing antibiotics, according to disease severity (implementa-
tion category between brackets), when oral therapy is possible:
• non-severe: metronidazole 500 mg tid orally for 10 days
(A-I)
• severe: vancomycin 125 mg qid* orally for 10 days (A-I)
*Oral vancomycin may be replaced by teicoplanin 100 mg
bid, if available.
CDI is judged to be severe when one or more of the
markers of severe colitis mentioned under ‘deﬁnitions’ is
present. It is unclear whether moderate disease in a patient
with other unfavourable prognostic factors, such as advanced
TABLE 6. Observational studies of treatment of recurrent CDI
Trial Treatment
Number
of patients
Failurea
(%)
Mean
follow-up
Antibiotics
Buggy et al. [53] Vancomycin 125 mg qid + rifampicin 600 mg bid, 7 days 7 0 12 months
McFarland et al. [7] Vancomycin 1–2 g/day 14 71 59 days
Vancomycin <1 g/day 48 54 59 days
Vancomycin ‡2 g/day 21 43 59 days
Vancomycin taper 29 31 80 days
Vancomycin pulse 7 14 80 days
Metronidazole <1 g/day 29 45 59 days
Metronidazole 1.5 g/day 5 40 59 days
Metronidazole 2 g/day 2 0 59 days
Johnson et al. [54] Vancomycin, 14 days, followed by rifaximin varying dose, 14 days 8 13 233 days
Garey et al. [55] Rifaximin 400 mg tid, 14 days, followed by rifaximin 200 mg tid, 14 days 5 0 310 days
Rifaximin 400 mg tid, 36 days 1 100 –
Probiotics
Gorbach et al. [56] Metronidazole or bacitracin, 10 days, followed by Lactobacillus GG 1010 CFU/day, 7–10 days 5 20 –
Biller et al. [57] Lactobacillus GG 6 · 108 CFU/day, 14 days 4 0 11 months
Faecal or bacterial instillation
Bowden et al. [58] Faecal enema 16 19 –
Tvede and Rask-Madsen [59] Faecal or bacterial enema 6 0 –
Lund-Tønnesen et al. [60] Faecal instillation through coloscope or gastrostoma 18 17 –
Aas et al. [61] Faecal instillation through nasogastric tube, median 3 courses 16 6 90 days
Jorup-Ro¨nstro¨m et al. [62] Faecal enema 5 0 –
Nieuwdorp et al. [63] Vancomycin 500 mg qid, followed by faecal instillation by nasoduodenal tube or colonoscopy 7 29 150 days
Borodyb Faecal enema 61 10 –
Lund-Tønnesenb Faecal instillation through nasojejunal tube 20 17 –
Mooreb Faecal enema 65 3 –
Aasb Faecal instillation through nasogastric tube 9 0 –
Macconnachie et al. [64] Faecal instillation through nasogastric tube 15 27 –
Immunotherapy
Leung et al. [65] iv gammaglobulin 400 mg/kg every 3 weeks, 4–6 months 5 0 5 months
Beales [66] iv gammaglobulin 400 mg/kg day 1 and 21 4 0 7.5 months
iv gammaglobulin, varying dose 5 40 2.8 months
Wilcox [67] iv gammaglobulin 300–500 mg/kg, 1–6 doses 5 40 86 days
McPherson et al. [68] iv gammaglobulin 150–400 mg/kg 14 71 6.6 months
aNon-response or relapse.
bAs reported by Bakken [69].
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age and comorbidity, should be regarded as severe. This is
left to the judgment of the treating physician. There is no
evidence that various genotypes of C. difﬁcile should be trea-
ted differently if disease severity does not differ.
When oral therapy is impossible, we recommend the fol-
lowing antibiotics, according to disease severity (implementa-
tion category between brackets):
• non-severe: metronidazole 500 mg tid intravenously for
10 days (A-III)
• severe: metronidazole 500 mg tid intravenously for
10 days (A-III) + intracolonic vancomycin 500 mg in
100 mL of normal saline every 4–12 h (C-III) and/or
vancomycin 500 mg qid by nasogastric tube (C-III)
Recommendations for surgical treatment of CDI
Colectomy should be performed to treat CDI in any of the
following situations:
• perforation of the colon
• systemic inﬂammation and deteriorating clinical condition
not responding to antibiotic therapy; this includes the
clinical diagnoses of toxic megacolon and severe ileus.
Since mortality following colectomy in patients with
advanced disease is high, it is recommended to operate at a
less severe stage. No deﬁnite recommendations on the tim-
ing of colectomy can be given. Serum lactate may, inter alia,
serve as a marker for severity, and one should attempt to
operate before the threshold of 5.0 mmol/L [79].
Recommendations for medical treatment of recurrent CDI
Observational data [12] suggest that the incidence of a
second recurrence after treatment of a ﬁrst recurrence with
oral metronidazole or vancomycin is similar. Therefore, we
recommend treating a ﬁrst recurrence of CDI as a ﬁrst
episode, unless disease has progressed from non-severe to
severe.
We recommend treatment of recurrent CDI with the fol-
lowing antibiotics (implementation category between brackets):
First recurrence:
See Recommendations for medical treatment of initial CDI.
Second recurrence and subsequent recurrences:
If oral therapy is possible:
• vancomycin 125 mg qid* orally for at least 10 days (B-II)
and consider a taper/pulse strategy (B-II)
*Oral vancomycin may be replaced by teicoplanin 100 mg
bid, if available.
If oral therapy is impossible:
• metronidazole 500 mg tid intravenously for 10–14 days
(A-III) + retention enema of vancomycin 500 mg in
100 mL of normal saline every 4–12 h (C-III) and/or
vancomycin 500 mg qid by nasogastric tube (C-III)
Recommendation for prophylaxis of CDI
Currently, there is no evidence that medical prophylaxis for
CDI is efﬁcacious and therefore we do not recommend pro-
phylactic antibiotics. Of course, other preventive measures
should be taken, such as hand hygiene of hospital personnel,
prompt isolation of patients suspected of having CDI, and
prudent use of antibiotics [81].
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